{"id":"https://openalex.org/W3033336486","doi":"https://doi.org/10.1111/1346-8138.15388","title":"Real\u2010world safety and efficacy data of ipilimumab in Japanese radically unresectable malignant melanoma patients: A postmarketing surveillance","display_name":"Real\u2010world safety and efficacy data of ipilimumab in Japanese radically unresectable malignant melanoma patients: A postmarketing surveillance","publication_year":2020,"publication_date":"2020-06-08","ids":{"openalex":"https://openalex.org/W3033336486","doi":"https://doi.org/10.1111/1346-8138.15388","mag":"3033336486","pmid":"https://pubmed.ncbi.nlm.nih.gov/32515086","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/7496696"},"language":"en","primary_location":{"id":"doi:10.1111/1346-8138.15388","doi":"https://doi.org/10.1111/1346-8138.15388","is_oa":true,"landing_page_url":"https://doi.org/10.1111/1346-8138.15388","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/1346-8138.15388","source":{"id":"https://openalex.org/S143887118","display_name":"The Journal of Dermatology","issn_l":"0385-2407","issn":["0385-2407","1346-8138"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Journal of Dermatology","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/1346-8138.15388","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5001893646","display_name":"Naoya Yamazaki","orcid":"https://orcid.org/0000-0002-9638-0428","observed_orcids":["https://orcid.org/0000-0002-9638-0428"]},"institutions":[{"id":"https://openalex.org/I4405285273","display_name":"National Cancer Center Hospital","ror":"https://ror.org/053hhpd64","country_code":"JP","type":"healthcare","lineage":["https://openalex.org/I4210087348","https://openalex.org/I4405285273"]}],"countries":["JP"],"is_corresponding":true,"raw_author_name":"Naoya Yamazaki","raw_affiliation_strings":["Department of Dermatologic Oncology, National Cancer Center Hospital, Tokyo, Japan"],"raw_orcid":"https://orcid.org/0000-0002-9638-0428","affiliations":[{"raw_affiliation_string":"Department of Dermatologic Oncology, National Cancer Center Hospital, Tokyo, Japan","institution_ids":["https://openalex.org/I4405285273"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5050952919","display_name":"Yoshio Kiyohara","orcid":"https://orcid.org/0000-0001-7335-4617","observed_orcids":["https://orcid.org/0000-0001-7335-4617"]},"institutions":[{"id":"https://openalex.org/I4210088324","display_name":"Shizuoka Cancer Center","ror":"https://ror.org/0042ytd14","country_code":"JP","type":"funder","lineage":["https://openalex.org/I4210088324"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Yoshio Kiyohara","raw_affiliation_strings":["Dermatology Division, Shizuoka Cancer Center Hospital, Nagaizumi, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dermatology Division, Shizuoka Cancer Center Hospital, Nagaizumi, Japan","institution_ids":["https://openalex.org/I4210088324"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5042799216","display_name":"Hisashi Uhara","orcid":"https://orcid.org/0000-0001-5391-3397","observed_orcids":["https://orcid.org/0000-0001-5391-3397"]},"institutions":[{"id":"https://openalex.org/I141882310","display_name":"Sapporo Medical University","ror":"https://ror.org/01h7cca57","country_code":"JP","type":"education","lineage":["https://openalex.org/I141882310"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Hisashi Uhara","raw_affiliation_strings":["Department of Dermatology, Sapporo Medical University, Sapporo, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Dermatology, Sapporo Medical University, Sapporo, Japan","institution_ids":["https://openalex.org/I141882310"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101094803","display_name":"Tetsuya Tsuchida","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I8588240","display_name":"Saitama Medical University","ror":"https://ror.org/04zb31v77","country_code":"JP","type":"education","lineage":["https://openalex.org/I8588240"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Tetsuya Tsuchida","raw_affiliation_strings":["Department of Dermatology, Saitama Medical University, Moroyama, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Dermatology, Saitama Medical University, Moroyama, Japan","institution_ids":["https://openalex.org/I8588240"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5055272589","display_name":"Keiko Maruyama","orcid":"https://orcid.org/0000-0003-4183-0345","observed_orcids":["https://orcid.org/0000-0003-4183-0345"]},"institutions":[{"id":"https://openalex.org/I4210148404","display_name":"Bristol-Myers Squibb (Japan)","ror":"https://ror.org/04dbmrm19","country_code":"JP","type":"company","lineage":["https://openalex.org/I4210091812","https://openalex.org/I4210148404"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Keiko Maruyama","raw_affiliation_strings":["Bristol-Myers Squibb K.K., Tokyo, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bristol-Myers Squibb K.K., Tokyo, Japan","institution_ids":["https://openalex.org/I4210148404"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5041940157","display_name":"\u91c8\u6c38\u5c1a\u6a39","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210148404","display_name":"Bristol-Myers Squibb (Japan)","ror":"https://ror.org/04dbmrm19","country_code":"JP","type":"company","lineage":["https://openalex.org/I4210091812","https://openalex.org/I4210148404"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Naoki Shakunaga","raw_affiliation_strings":["Bristol-Myers Squibb K.K., Tokyo, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bristol-Myers Squibb K.K., Tokyo, Japan","institution_ids":["https://openalex.org/I4210148404"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5000277658","display_name":"Eijun Itakura","orcid":"https://orcid.org/0000-0003-3059-7090","observed_orcids":["https://orcid.org/0000-0003-3059-7090"]},"institutions":[{"id":"https://openalex.org/I4210148404","display_name":"Bristol-Myers Squibb (Japan)","ror":"https://ror.org/04dbmrm19","country_code":"JP","type":"company","lineage":["https://openalex.org/I4210091812","https://openalex.org/I4210148404"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Eijun Itakura","raw_affiliation_strings":["Bristol-Myers Squibb K.K., Tokyo, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bristol-Myers Squibb K.K., Tokyo, Japan","institution_ids":["https://openalex.org/I4210148404"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5066970622","display_name":"Akira Komoto","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210148404","display_name":"Bristol-Myers Squibb (Japan)","ror":"https://ror.org/04dbmrm19","country_code":"JP","type":"company","lineage":["https://openalex.org/I4210091812","https://openalex.org/I4210148404"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Akira Komoto","raw_affiliation_strings":["Bristol-Myers Squibb K.K., Tokyo, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bristol-Myers Squibb K.K., Tokyo, Japan","institution_ids":["https://openalex.org/I4210148404"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":5,"corresponding_author_ids":["https://openalex.org/A5001893646"],"corresponding_institution_ids":["https://openalex.org/I4405285273"],"apc_list":{"value":3630,"currency":"USD","value_usd":3630},"apc_paid":{"value":3630,"currency":"USD","value_usd":3630},"fwci":1.1733,"has_fulltext":true,"cited_by_count":18,"citation_normalized_percentile":{"value":0.79976575,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":93,"max":98},"biblio":{"volume":"47","issue":"8","first_page":"834","last_page":"848"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9429000020027161,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9429000020027161,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10392","display_name":"Cutaneous Melanoma Detection and Management","score":0.05460000038146973,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11533","display_name":"Melanoma and MAPK Pathways","score":0.0010000000474974513,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/ipilimumab","display_name":"ipilimumab","score":0.9990000128746033},{"id":"https://openalex.org/keywords/melanoma","display_name":"melanoma","score":0.7889999747276306},{"id":"https://openalex.org/keywords/mucosal-melanoma","display_name":"mucosal melanoma","score":0.7329999804496765},{"id":"https://openalex.org/keywords/acral-lentiginous-melanoma","display_name":"acral lentiginous melanoma","score":1.0},{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitors","display_name":"immune checkpoint inhibitors","score":0.9430000185966492},{"id":"https://openalex.org/keywords/ctla-4-blockade","display_name":"CTLA-4 blockade","score":0.8730000257492065},{"id":"https://openalex.org/keywords/adverse-drug-reactions","display_name":"adverse drug reactions","score":0.9520000219345093},{"id":"https://openalex.org/keywords/serious-adverse-drug-reactions","display_name":"serious adverse drug reactions","score":0.6790000200271606},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.8140000104904175},{"id":"https://openalex.org/keywords/real-world-efficacy-and-safety","display_name":"real-world efficacy and safety","score":0.7120000123977661},{"id":"https://openalex.org/keywords/post-marketing-surveillance","display_name":"post-marketing surveillance","score":0.9309999942779541},{"id":"https://openalex.org/keywords/japan","display_name":"Japan","score":0.5299999713897705},{"id":"https://openalex.org/keywords/hepatotoxicity","display_name":"hepatotoxicity","score":0.527999997138977},{"id":"https://openalex.org/keywords/colitis","display_name":"colitis","score":0.7490000128746033},{"id":"https://openalex.org/keywords/diarrhea","display_name":"diarrhea","score":0.7250000238418579},{"id":"https://openalex.org/keywords/treatment-tolerability","display_name":"treatment tolerability","score":0.41600000858306885},{"id":"https://openalex.org/keywords/recurrent-melanoma","display_name":"recurrent melanoma","score":0.4659999907016754}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9285895824432373},{"id":"https://openalex.org/C2781433595","wikidata":"https://www.wikidata.org/wiki/Q2459042","display_name":"Ipilimumab","level":4,"score":0.920944094657898},{"id":"https://openalex.org/C197636746","wikidata":"https://www.wikidata.org/wiki/Q7234359","display_name":"Postmarketing surveillance","level":3,"score":0.6968618035316467},{"id":"https://openalex.org/C2777658100","wikidata":"https://www.wikidata.org/wiki/Q180614","display_name":"Melanoma","level":2,"score":0.6883671283721924},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6686468124389648},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5492007732391357},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.5088122487068176},{"id":"https://openalex.org/C61511704","wikidata":"https://www.wikidata.org/wiki/Q1671857","display_name":"Incidence (geometry)","level":2,"score":0.46456044912338257},{"id":"https://openalex.org/C2780030458","wikidata":"https://www.wikidata.org/wiki/Q7041828","display_name":"Nivolumab","level":4,"score":0.443120539188385},{"id":"https://openalex.org/C2779802037","wikidata":"https://www.wikidata.org/wiki/Q40878","display_name":"Diarrhea","level":2,"score":0.42602425813674927},{"id":"https://openalex.org/C207103383","wikidata":"https://www.wikidata.org/wiki/Q3930246","display_name":"Hazard ratio","level":3,"score":0.41339272260665894},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.36665284633636475},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.2572129964828491},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.24069735407829285},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.11349987983703613},{"id":"https://openalex.org/C121332964","wikidata":"https://www.wikidata.org/wiki/Q413","display_name":"Physics","level":0,"score":0.0},{"id":"https://openalex.org/C120665830","wikidata":"https://www.wikidata.org/wiki/Q14620","display_name":"Optics","level":1,"score":0.0},{"id":"https://openalex.org/C44249647","wikidata":"https://www.wikidata.org/wiki/Q208498","display_name":"Confidence interval","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D000074324","descriptor_name":"Ipilimumab","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007564","descriptor_name":"Japan","qualifier_ui":"Q000453","qualifier_name":"epidemiology","is_major_topic":false},{"descriptor_ui":"D008545","descriptor_name":"Melanoma","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011446","descriptor_name":"Prospective Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012878","descriptor_name":"Skin Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true}],"locations_count":3,"locations":[{"id":"doi:10.1111/1346-8138.15388","doi":"https://doi.org/10.1111/1346-8138.15388","is_oa":true,"landing_page_url":"https://doi.org/10.1111/1346-8138.15388","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/1346-8138.15388","source":{"id":"https://openalex.org/S143887118","display_name":"The Journal of Dermatology","issn_l":"0385-2407","issn":["0385-2407","1346-8138"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Journal of Dermatology","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:7496696","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/7496696","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"J Dermatol","raw_type":"Text"},{"id":"pmid:32515086","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/32515086","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Journal of dermatology","raw_type":"Journal Article"}],"best_oa_location":{"id":"doi:10.1111/1346-8138.15388","doi":"https://doi.org/10.1111/1346-8138.15388","is_oa":true,"landing_page_url":"https://doi.org/10.1111/1346-8138.15388","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/1346-8138.15388","source":{"id":"https://openalex.org/S143887118","display_name":"The Journal of Dermatology","issn_l":"0385-2407","issn":["0385-2407","1346-8138"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Journal of Dermatology","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"sustainable_development_goals_aurora":[{"id":"https://metadata.un.org/sdg/3","score":0.8199999928474426,"display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/observational-study","display_name":"Observational Study"}],"awards":[],"funders":[{"id":"https://openalex.org/F4320307115","display_name":"Bristol-Myers Squibb","ror":"https://ror.org/00gtmwv55"},{"id":"https://openalex.org/F4320311653","display_name":"Taiho Pharmaceutical","ror":"https://ror.org/02v50dx14"},{"id":"https://openalex.org/F4320322359","display_name":"Kyowa Hakko Kirin","ror":"https://ror.org/0586k5242"},{"id":"https://openalex.org/F4320327845","display_name":"Ono Pharmaceutical","ror":"https://ror.org/022jefx64"},{"id":"https://openalex.org/F4320332736","display_name":"Novartis Pharma","ror":"https://ror.org/0013shd50"},{"id":"https://openalex.org/F4320333003","display_name":"Chugai Pharmaceutical","ror":"https://ror.org/01vepzj85"}],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W3033336486.pdf","grobid_xml":"https://content.openalex.org/works/W3033336486.grobid-xml"},"referenced_works_count":26,"referenced_works":["https://openalex.org/W2000145027","https://openalex.org/W2034248634","https://openalex.org/W2051772831","https://openalex.org/W2097995306","https://openalex.org/W2111877246","https://openalex.org/W2130723808","https://openalex.org/W2166662937","https://openalex.org/W2166667372","https://openalex.org/W2312943839","https://openalex.org/W2323608210","https://openalex.org/W2400472415","https://openalex.org/W2515491659","https://openalex.org/W2553340100","https://openalex.org/W2733884328","https://openalex.org/W2753432434","https://openalex.org/W2770404972","https://openalex.org/W2793007221","https://openalex.org/W2891480230","https://openalex.org/W2901290714","https://openalex.org/W2903486314","https://openalex.org/W2905314444","https://openalex.org/W2912374321","https://openalex.org/W2933878484","https://openalex.org/W2945251690","https://openalex.org/W2973740076","https://openalex.org/W3043703771"],"related_works":["https://openalex.org/W4381715310","https://openalex.org/W2130723808","https://openalex.org/W1989182836","https://openalex.org/W2112403746","https://openalex.org/W7097930689","https://openalex.org/W2200809230","https://openalex.org/W7099346654","https://openalex.org/W2142506385","https://openalex.org/W4288067023","https://openalex.org/W2999612708"],"abstract_inverted_index":{"Treatment":[0],"with":[1,10,96,103,251,265,276],"immune":[2],"checkpoint":[3],"inhibitors":[4],"has":[5],"improved":[6],"prognosis":[7],"among":[8],"patients":[9,95,122,162,250,264,275],"cutaneous":[11],"melanoma,":[12],"but":[13],"there":[14],"are":[15],"still":[16],"unmet":[17],"medical":[18],"needs":[19],"in":[20,52,54,88,92,105,226,249,263,274,288],"Japan,":[21],"especially":[22],"for":[23,56,291],"mucosal":[24,252],"melanoma":[25,29,100,145,253,255],"and":[26,45,81,114,154,166,175,180,187,194,213,246,254,260,266,269,271,277,285],"acral":[27],"lentiginous":[28],"(ALM)":[30],"subtypes.":[31],"Ipilimumab,":[32],"a":[33,89],"fully":[34],"human":[35],"monoclonal":[36],"antibody":[37],"that":[38],"specifically":[39],"blocks":[40],"cytotoxic":[41],"T-lymphocyte-associated":[42],"antigen":[43],"4":[44],"potentiates":[46],"antitumor":[47],"T-cell":[48],"response,":[49],"was":[50,178,235,244,283],"approved":[51],"Japan":[53,106],"2015":[55,113],"the":[57,73,108,147,151,229,257],"treatment":[58,102],"of":[59,76,86,141,146,150,173,200,219,256],"radically":[60,97],"unresectable":[61,98],"malignant":[62,99],"melanoma.":[63],"This":[64],"postmarketing":[65],"surveillance":[66],"(prospective,":[67],"non-interventional,":[68],"multicenter,":[69],"observational":[70],"study)":[71],"evaluated":[72],"safety":[74],"(occurrence":[75],"adverse":[77],"drug":[78],"reactions":[79],"[ADR])":[80],"efficacy":[82,287],"(overall":[83],"survival":[84],"[OS])":[85],"ipilimumab":[87,104],"real-world":[90],"setting":[91],"Japan.":[93],"All":[94],"undergoing":[101],"during":[107],"registration":[109],"period":[110],"between":[111],"August":[112],"February":[115],"2017":[116],"were":[117,123,126,190,203,225],"enrolled.":[118],"In":[119],"total,":[120],"547":[121],"analyzed;":[124],"67.5%":[125],"60":[127],"years":[128],"old":[129],"or":[130,224],"more,":[131],"85.7%":[132],"had":[133,144,156,163,222],"an":[134],"Eastern":[135],"Cooperative":[136],"Oncology":[137],"Group":[138],"performance":[139],"status":[140],"0-1,":[142],"50.3%":[143],"skin":[148],"(mainly":[149],"ALM":[152],"subtype)":[153],"73.5%":[155],"negative":[157],"BRAF":[158],"mutation":[159],"status.":[160],"Most":[161,218],"experienced":[164],"recurrence":[165],"received":[167],"multiple":[168],"treatments.":[169],"The":[170,183,196,232],"overall":[171],"incidence":[172],"ADR":[174,177,186,189,199,205,208,211,216],"serious":[176,188,279],"69.5%":[179],"40.8%,":[181],"respectively.":[182,281],"most":[184,197],"common":[185,198],"liver":[191],"disorder,":[192],"colitis":[193],"diarrhea.":[195],"special":[201],"interest":[202],"liver-related":[204],"(22.5%),":[206],"skin-related":[207],"(22.1%),":[209],"gastrointestinal-related":[210],"(20.3%)":[212],"endocrine":[214],"system-related":[215],"(16.3%).":[217],"these":[220,292],"events":[221],"recovered":[223],"remission":[227],"by":[228],"last":[230],"evaluation.":[231],"median":[233],"OS":[234,243,290],"7.52":[236],"months":[237,248,262,273],"(95%":[238],"confidence":[239],"interval,":[240],"6.47-8.74).":[241],"Median":[242],"6.31":[245],"8.44":[247],"skin;":[258],"9.43":[259],"3.75":[261],"without":[267,278],"ADR;":[268],"10.32":[270],"6.11":[272],"ADR,":[280],"Ipilimumab":[282],"tolerable":[284],"showed":[286],"improving":[289],"patients.":[293]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":2},{"year":2024,"cited_by_count":2},{"year":2023,"cited_by_count":2},{"year":2022,"cited_by_count":5},{"year":2021,"cited_by_count":2},{"year":2020,"cited_by_count":4}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2020-06-12T00:00:00"}